Search Results - "FURST, Daniel"

Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease by Roofeh, David, Lin, Celia J. F., Goldin, Jonathan, Kim, Grace Hyun, Furst, Daniel E., Denton, Christopher P., Huang, Suiyuan, Khanna, Dinesh

“…Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc). This effect has…”
Get full text

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis by Furst, Daniel E., MD

“…Objectives To assess the risk of serious and nonserious bacterial and viral infections associated with the use of biologic therapy (abatacept, adalimumab,…”
Get full text

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis by Singh, Jasvinder A., Saag, Kenneth G., Bridges, S. Louis, Akl, Elie A., Bannuru, Raveendhara R., Sullivan, Matthew C., Vaysbrot, Elizaveta, McNaughton, Christine, Osani, Mikala, Shmerling, Robert H., Curtis, Jeffrey R., Furst, Daniel E., Parks, Deborah, Kavanaugh, Arthur, O'Dell, James, King, Charles, Leong, Amye, Matteson, Eric L., Schousboe, John T., Drevlow, Barbara, Ginsberg, Seth, Grober, James, St.Clair, E. William, Tindall, Elizabeth, Miller, Amy S., McAlindon, Timothy

“…Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to…”
Get full text

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial by Khanna, Dinesh, Lin, Celia J F, Furst, Daniel E, Wagner, Bridget, Zucchetto, Mauro, Raghu, Ganesh, Martinez, Fernando J, Goldin, Jonathan, Siegel, Jeffrey, Denton, Christopher P

“…Tocilizumab, an anti-IL-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients…”
Get full text

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period by Emery, Paul, Burmester, Gerd R, Bykerk, Vivian P, Combe, Bernard G, Furst, Daniel E, Barré, Emilie, Karyekar, Chetan S, Wong, Dennis A, Huizinga, Tom W J

“…To evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid…”
Get more information

Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets by Furst, Daniel E, Emery, Paul

“…Biologic therapies that target pathogenic cytokines such as TNF, IL-1β or IL-6 have greatly improved the treatment of RA. Unfortunately, not all RA patients…”
Get full text

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial by Khanna, Dinesh, Prof, Denton, Christopher P, Prof, Jahreis, Angelika, MD, van Laar, Jacob M, Prof, Frech, Tracy M, MD, Anderson, Marina E, FRCP, Baron, Murray, MD, Chung, Lorinda, MD, Fierlbeck, Gerhard, MD, Lakshminarayanan, Santhanam, MD, Allanore, Yannick, Prof, Pope, Janet E, MD, Riemekasten, Gabriela, Prof, Steen, Virginia, Prof, Müller-Ladner, Ulf, Prof, Lafyatis, Robert, MD, Stifano, Giuseppina, MD, Spotswood, Helen, PhD, Chen-Harris, Haiyin, PhD, Dziadek, Sebastian, PhD, Morimoto, Alyssa, PhD, Sornasse, Thierry, PhD, Siegel, Jeffrey, MD, Furst, Daniel E, Prof

“…Summary Background Systemic sclerosis is a rare disabling autoimmune disease with few treatment options. The efficacy and safety of tocilizumab, an interleukin…”
Get full text

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis by Singh, Jasvinder A., Saag, Kenneth G., Bridges, S. Louis, Akl, Elie A., Bannuru, Raveendhara R., Sullivan, Matthew C., Vaysbrot, Elizaveta, McNaughton, Christine, Osani, Mikala, Shmerling, Robert H., Curtis, Jeffrey R., Furst, Daniel E., Parks, Deborah, Kavanaugh, Arthur, O'Dell, James, King, Charles, Leong, Amye, Matteson, Eric L., Schousboe, John T., Drevlow, Barbara, Ginsberg, Seth, Grober, James, St.Clair, E. William, Tindall, Elizabeth, Miller, Amy S., McAlindon, Timothy

“…Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to…”
Get full text

Targeting inflammatory pathways in axial spondyloarthritis by Furst, Daniel E, Louie, James S

“…The triggers and pathogenesis of axial spondyloarthritis (axSpA) are not yet completely understood. However, therapeutic agents targeting tumor necrosis…”
Get full text

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years by van Vollenhoven, Ronald F, Fleischmann, Roy M, Furst, Daniel E, Lacey, Stuart, Lehane, Patricia B

“…Final evaluation of the longterm safety of rituximab (RTX) in rheumatoid arthritis (RA) up to 11 years. Pooled observed case analysis of data from patients…”
Get full text

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative by van den Hoogen, Frank, Khanna, Dinesh, Fransen, Jaap, Johnson, Sindhu R, Baron, Murray, Tyndall, Alan, Matucci-Cerinic, Marco, Naden, Raymond P, Medsger, Jr, Thomas A, Carreira, Patricia E, Riemekasten, Gabriela, Clements, Philip J, Denton, Christopher P, Distler, Oliver, Allanore, Yannick, Furst, Daniel E, Gabrielli, Armando, Mayes, Maureen D, van Laar, Jacob M, Seibold, James R, Czirjak, Laszlo, Steen, Virginia D, Inanc, Murat, Kowal-Bielecka, Otylia, Müller-Ladner, Ulf, Valentini, Gabriele, Veale, Douglas J, Vonk, Madelon C, Walker, Ulrich A, Chung, Lorinda, Collier, David H, Ellen Csuka, Mary, Fessler, Barri J, Guiducci, Serena, Herrick, Ariane, Hsu, Vivien M, Jimenez, Sergio, Kahaleh, Bashar, Merkel, Peter A, Sierakowski, Stanislav, Silver, Richard M, Simms, Robert W, Varga, John, Pope, Janet E

“…The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc…”
Get more information

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial by Khanna, Dinesh, Spino, Cathie, Johnson, Sindhu, Chung, Lorinda, Whitfield, Michael L., Denton, Christopher P., Berrocal, Veronica, Franks, Jennifer, Mehta, Bhavan, Molitor, Jerry, Steen, Virginia D., Lafyatis, Robert, Simms, Robert W., Gill, Anna, Kafaja, Suzanne, Frech, Tracy M., Hsu, Vivien, Domsic, Robyn T., Pope, Janet E., Gordon, Jessica K., Mayes, Maureen D., Schiopu, Elena, Young, Amber, Sandorfi, Nora, Park, Jane, Hant, Faye N., Bernstein, Elana J., Chatterjee, Soumya, Castelino, Flavia V., Ajam, Ali, Wang, Yue, Wood, Tammara, Allanore, Yannick, Matucci‐Cerinic, Marco, Distler, Oliver, Singer, Ora, Bush, Erica, Fox, David A., Furst, Daniel E.

“…Objective T cells play a key role in the pathogenesis of early systemic sclerosis. This study was undertaken to assess the safety and efficacy of abatacept in…”
Get full text

Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood by Wang, Yukai, Xie, Xuezhen, Zhang, Chengpeng, Su, Miaotong, Gao, Sini, Wang, Jing, Lu, Changhao, Lin, Qisheng, Lin, Jianqun, Matucci-Cerinic, Marco, Furst, Daniel E, Zhang, Guohong

“…Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) share many clinical manifestations and serological features…”
Get more information

Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials by Senftleber, Ninna K, Nielsen, Sabrina M, Andersen, Jens R, Bliddal, Henning, Tarp, Simon, Lauritzen, Lotte, Furst, Daniel E, Suarez-Almazor, Maria E, Lyddiatt, Anne, Christensen, Robin

“…Arthritis patients often take fish oil supplements to alleviate symptoms, but limited evidence exists regarding their efficacy. The objective was to evaluate…”
Get full text

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) by Khanna, Dinesh, Denton, Christopher P, Lin, Celia J F, van Laar, Jacob M, Frech, Tracy M, Anderson, Marina E, Baron, Murray, Chung, Lorinda, Fierlbeck, Gerhard, Lakshminarayanan, Santhanam, Allanore, Yannick, Pope, Janet E, Riemekasten, Gabriela, Steen, Virginia, Müller-Ladner, Ulf, Spotswood, Helen, Burke, Laura, Siegel, Jeffrey, Jahreis, Angelika, Furst, Daniel E

“…Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) in a phase II study. Patients with SSc were treated for 48 weeks in an…”
Get more information

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts by Volkmann, Elizabeth R, Tashkin, Donald P, Sim, Myung, Li, Ning, Goldmuntz, Ellen, Keyes-Elstein, Lynette, Pinckney, Ashley, Furst, Daniel E, Clements, Philip J, Khanna, Dinesh, Steen, Virginia, Schraufnagel, Dean E, Arami, Shiva, Hsu, Vivien, Roth, Michael D, Elashoff, Robert M, Sullivan, Keith M

“…To assess survival and identify predictors of survival in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) who participated in the…”
Get more information

High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference by Li, Hongyan, Furst, Daniel E, Jin, Hongtao, Sun, Chao, Wang, Xiaoping, Yang, Lin, He, Jingjing, Wang, Yanru, Liu, Aijing

“…Thickened skin is a major clinical feature in patients with systemic sclerosis (SSc). We investigated changes of skin thickness in patients with SSc using both…”
Get full text

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial by Khanna, Dinesh, Lin, Celia J F, Furst, Daniel E, Goldin, Jonathan, Kim, Grace, Kuwana, Masataka, Allanore, Yannick, Matucci-Cerinic, Marco, Distler, Oliver, Shima, Yoshihito, van Laar, Jacob M, Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, Denton, Christopher P, Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Allanore, Yannick, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Matucci-Cerinic, Marco, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Kuwana, Masataka, Shima, Yoshihito, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, van Laar, Jacob M., Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Distler, Oliver, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Denton, Christopher P., Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Furst, Daniel E., Kafaja, Suzanne, Khan, M. Faisal, Khanna, Dinesh, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, Steen, Virginia D.

“…A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated…”
Get full text

Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome highlight T cell-initiated autoimmunity by Wang, Yukai, Chen, Shaoqi, Chen, Jingyao, Xie, Xuezhen, Gao, Sini, Zhang, Chengpeng, Zhou, Songxia, Wang, Jing, Mai, Ruiqin, Lin, Qisheng, Lin, Jianqun, Matucci-Cerinic, Marco, Zhang, Guohong, Furst, Daniel E

“…Familial aggregation of primary Sjögren's syndrome (pSS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and co-aggregation of these autoimmune…”
Get more information

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis by Spiera, Robert, Hummers, Laura, Chung, Lorinda, Frech, Tracy M., Domsic, Robyn, Hsu, Vivien, Furst, Daniel E., Gordon, Jessica, Mayes, Maureen, Simms, Robert, Lafyatis, Robert, Martyanov, Viktor, Wood, Tammara, Whitfield, Michael L., Constantine, Scott, Lee, Elizabeth, Dgetluck, Nancy, White, Barbara

“…Objective To assess the safety and efficacy of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc). Methods A randomized, double‐blind,…”
Get full text